Validity of self-reported genetic counseling and genetic testing use among breast cancer survivors
Despite the value of genetic counseling (GC) and genetic testing (GT) for high-risk breast cancer survivors, little is known about their uptake and validity of self-report data. This study evaluated the accuracy of self-reported genetic counseling and testing rates among breast cancer survivors.
The current analysis focused on Stage 0-III female breast cancer survivors who were identified from an academic medical center’s cancer registry and responded to a mailed survey (N = 452). Self-reported rates of GC and GT were validated using information from the electronic medical record.
Overall, 30.8 % of survivors reported having seen a genetic counselor in the time period after their breast cancer diagnosis and 33.6 % noted having a genetic test. Concordance and specificity were good for both genetic questions; concordance agreements ranged from 86–88 %, while specificity was 83–86 %. Sensitivity (97–98 %) and negative predictive values (99 %) were excellent, while the positive predictive values for both GC and GT were poor (59–63 %).
Among breast cancer survivors, self-reports of GC and GT were generally accurate, although a subset of respondents overestimated genetic service utilization. Future work should focus on validating GC and GT self-reports in medically underserved populations.
Implications for Cancer Survivors
Genetic counseling and testing are valuable aspects of survivorship care for high-risk breast cancer survivors; accurate understanding of their use is important for survivors, clinicians, and researchers.
KeywordsGenetic counseling Genetic testing Electronic medical record Validation
- 1.American Cancer Society, “Breast Cancer: Detailed Guide,” 2012. [Online]. Available: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics. [Accessed 22 February 2013].
- 3.NCCN, Inc., NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. Inc, Fort Washington: National Comprehensive Cancer Network; 2012.Google Scholar
- 5.National Cancer Institute, “Genetics of Breast and Ovarian Cancer (PDQ®),” 21 December 2012. [Online]. http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page2/AllPages. [Accessed 22 February 2013].
- 6.National Cancer Institute, “BRCA1 and BRCA2: Cancer Risk and Genetic Testing,” 29 May 2009. [Online].http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA#r6. [Accessed 22 February 2013].
- 12.Carpentier MY, Tiro JA, Savas SL, Bartholomew LK, Melhado TV, Coan SP, Argenbright KE, Vernon SW. Are cancer registries a viable tool for cancer survivor outreach? A feasibility study. J Cancer Surviv. 2013;7(1):155–63.Google Scholar
- 13.Tisnado DM, Adams JL, Liu H, Damber CL, Chen WP, Hu FA, Carlisle DM, Mangione CM, Kahn KL. What is the concordance between the medical record and patient self-report as data sources for ambulatory care?. Med Care. 2006;44(2):132–40.Google Scholar
- 16.Jolie A. My medical choice. Los Angeles: The New York Times: 2013. p. A25.Google Scholar